ARTICLE | Company News
SciClone, RESprotect deal
July 4, 2011 7:00 AM UTC
RESprotect said SciClone returned North American rights to pancreatic cancer candidate RP101. SciClone discontinued a Phase II trial of the small molecule that binds to heat shock protein 27 (Hsp27)...